GlassScriptPhysician profile
Dallas Shone
NPI 1043213101
$7,940.13
in general payments reported to CMS, 2019-2025
41 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $650 · 2021: $1,348 · 2022: $1,414 · 2023: $1,371 · 2024: $1,297 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,942.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,969.89 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,174.98 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $935.67 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $629.90 | 2020-2025 | |
| Qol Medical, LLC | $303.48 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $269.60 | 2020-2024 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $236.12 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $229.75 | 2020-2025 | Rebyota |
| Celgene Corporation | $218.47 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $193.66 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $153.16 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $152.53 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $125.68 | 2020-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $123.71 | 2019-2022 | |
| Evoke Pharma, INC. | $121.52 | 2024-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $117.16 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $110.16 | 2019-2023 | Linzess |
| Braintree Laboratories, INC. | $76.93 | 2019-2024 | Sutab, Suflave |
| Daiichi Sankyo INC. | $75.86 | 2021-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $75.35 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $69.09 | 2019-2025 | Wegovy |
| Genzyme Corporation | $62.18 | 2022-2024 | |
| Celltrion USA INC. | $62.00 | 2024-2025 | Vegzelma |
| Conmed Corporation | $49.46 | 2022 | |
| Lilly USA, LLC | $38.47 | 2024 | Omvoh |
| Redhill Biopharma INC. | $36.04 | 2021 | |
| Olympus America INC. | $34.66 | 2023-2025 | Uretero-Reno Fiberscope |
| Ipsen Biopharmaceuticals, INC | $32.80 | 2024-2025 | Iqirvo |
| Romark Laboratories, Lc | $32.51 | 2020 | |
| Medline Industries LP | $31.99 | 2025 | |
| Madrigal Pharmaceuticals | $29.84 | 2024 | Resmetirom |
| Echosens North America, INC. | $24.45 | 2023 | Fibroscan |
| Mirum Pharmaceuticals, INC. | $20.67 | 2025 | Livmarli |
| Alfasigma USA, INC. | $19.34 | 2020 | |
| Alnylam Pharmaceuticals INC. | $17.34 | 2020 | |
| Sandoz INC. | $16.85 | 2024 | Hyrimoz |
| Allergan, INC. | $16.82 | 2020 | |
| Fresenius Kabi USA, LLC | $16.40 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.15 | 2023 | Cyltezo |
| Shionogi INC | $10.87 | 2019 | |
| Organon LLC | $8.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dallas Shone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.